RU2010114007A - Применение комбинации пептидов cart в качестве терапевтического средства - Google Patents
Применение комбинации пептидов cart в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010114007A RU2010114007A RU2010114007/15A RU2010114007A RU2010114007A RU 2010114007 A RU2010114007 A RU 2010114007A RU 2010114007/15 A RU2010114007/15 A RU 2010114007/15A RU 2010114007 A RU2010114007 A RU 2010114007A RU 2010114007 A RU2010114007 A RU 2010114007A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- cys
- gly
- pharmaceutical composition
- combination according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 4
- 208000035473 Communicable disease Diseases 0.000 claims abstract 4
- 208000019693 Lung disease Diseases 0.000 claims abstract 4
- 208000019622 heart disease Diseases 0.000 claims abstract 4
- 235000020256 human milk Nutrition 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 208000030159 metabolic disease Diseases 0.000 claims abstract 4
- 230000004770 neurodegeneration Effects 0.000 claims abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 4
- 208000019553 vascular disease Diseases 0.000 claims abstract 4
- 239000007788 liquid Substances 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 239000007853 buffer solution Substances 0.000 claims abstract 2
- 239000002577 cryoprotective agent Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- -1 lyoprotectant Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
Abstract
1. Комбинация пептидов Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-OH и Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu-OH или их солей или гидратов. ! 2. Комбинация по п.1, где пептиды содержатся в комбинации в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Комбинация по п.1 для применения в лекарственном средстве. ! 4. Применение комбинации по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов, болезни обмена веществ и злокачественной опухоли. ! 5. Применение комбинации по п.4, где аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов, болезнь обмена веществ или злокачественная опухоль выбраны из инфекции вирусом гепатита B, острого гепатита, хронического гепатита, острой печеночной недостаточности, цирроза печени и злокачественной опухоли, вызываемой инфекцией вирусом гепатита B. ! 6. Применение комбинации по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение комбинации по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, содержащая комбинацию по п.1 или 2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, эксципиентом и/или разбавителем. ! 9. Фармацевтическая �
Claims (13)
1. Комбинация пептидов Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-OH и Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu-OH или их солей или гидратов.
2. Комбинация по п.1, где пептиды содержатся в комбинации в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%.
3. Комбинация по п.1 для применения в лекарственном средстве.
4. Применение комбинации по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов, болезни обмена веществ и злокачественной опухоли.
5. Применение комбинации по п.4, где аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов, болезнь обмена веществ или злокачественная опухоль выбраны из инфекции вирусом гепатита B, острого гепатита, хронического гепатита, острой печеночной недостаточности, цирроза печени и злокачественной опухоли, вызываемой инфекцией вирусом гепатита B.
6. Применение комбинации по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение комбинации по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая комбинацию по п.1 или 2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 дополнительно содержащая, по меньшей мере, один криопротектор или лиопротектор.
10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме лиофилизата или жидкого буферного раствора.
12. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и детям дошкольного возраста.
13. Фармацевтическая композиция по п.8 или 9, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017750.6 | 2007-09-11 | ||
| EP07017750 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010114007A true RU2010114007A (ru) | 2011-10-20 |
Family
ID=40293586
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113989/15A RU2010113989A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010114007/15A RU2010114007A (ru) | 2007-09-11 | 2008-09-09 | Применение комбинации пептидов cart в качестве терапевтического средства |
| RU2010113969/15A RU2010113969A (ru) | 2007-09-11 | 2008-09-09 | Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств |
| RU2010114059/15A RU2010114059A (ru) | 2007-09-11 | 2008-09-09 | Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства |
| RU2010114034/15A RU2010114034A (ru) | 2007-09-11 | 2008-09-09 | Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113989/15A RU2010113989A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113969/15A RU2010113969A (ru) | 2007-09-11 | 2008-09-09 | Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств |
| RU2010114059/15A RU2010114059A (ru) | 2007-09-11 | 2008-09-09 | Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства |
| RU2010114034/15A RU2010114034A (ru) | 2007-09-11 | 2008-09-09 | Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20100204135A1 (ru) |
| EP (6) | EP2187931A2 (ru) |
| JP (5) | JP5395793B2 (ru) |
| KR (5) | KR20100058556A (ru) |
| AT (1) | ATE553772T1 (ru) |
| AU (5) | AU2008297535A1 (ru) |
| CA (5) | CA2698912A1 (ru) |
| RU (5) | RU2010113989A (ru) |
| WO (16) | WO2009039969A2 (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2362604B1 (es) * | 2009-12-22 | 2012-06-28 | Bcn Peptides, S.A. | Formulación tópica oftálmica de péptidos. |
| WO2011085957A2 (en) * | 2010-01-13 | 2011-07-21 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| HK1199261A1 (en) * | 2011-09-26 | 2015-06-26 | Galera Labs, Llc | Methods for treatment of diseases |
| WO2013067420A1 (en) * | 2011-11-03 | 2013-05-10 | Tumlin James A | Acth for treatment of kidney disease |
| US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| SMT201900024T1 (it) * | 2012-01-17 | 2019-05-10 | Tyme Inc | Terapia combinata per il trattamento di cancro |
| US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| RU2528337C1 (ru) * | 2013-09-25 | 2014-09-10 | Халлар Абдумуслимович Алиханов | Средство для лечения аутоиммунных заболеваний |
| WO2016044707A1 (en) | 2014-09-18 | 2016-03-24 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| JP2021501796A (ja) * | 2017-11-02 | 2021-01-21 | タルシウス ファーマ リミテッド | 眼炎症を治療するためのホスホリルコリン−タフトシン複合体 |
| CN110438066B (zh) * | 2019-08-19 | 2021-01-12 | 杭州百凌生物科技有限公司 | 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用 |
| CN115150565B (zh) * | 2022-09-01 | 2023-01-13 | 宏晶微电子科技股份有限公司 | 信号处理方法、装置及系统 |
| CN119119191B (zh) * | 2024-09-13 | 2025-04-01 | 渤海大学 | 一种海参肠多肽及其在制备胃部疾病药物中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
| US5266562A (en) * | 1987-11-19 | 1993-11-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-inflammatory agents |
| EP0436611A4 (en) * | 1988-09-28 | 1992-03-11 | Peptide Technology Ltd | Compound and method for the retardation of collagen cross-linking |
| US5049655A (en) * | 1989-03-22 | 1991-09-17 | The Salk Institute For Biological Studies | Melanin-concentrating hormones |
| US5198423A (en) * | 1989-05-26 | 1993-03-30 | Takara Shuzo Co., Ltd. | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin |
| US6391343B1 (en) * | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
| US5411943A (en) * | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
| DE4316293C2 (de) * | 1993-05-14 | 1996-05-09 | Jobst Krauskopf | Verwendung einer Kombination von Anserin/Carnosin und Hypotaurin/Taurin zur Bekämpfung entzündlicher Erkrankungen |
| AU693143B2 (en) * | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
| ATE193636T1 (de) | 1996-09-24 | 2000-06-15 | Nestle Sa | Milchaustauschprodukt und verfahren zu dessen herstellung |
| AU6393498A (en) * | 1997-03-26 | 1998-10-20 | Novo Nordisk A/S | Polypeptide with appetite regulating activity |
| US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| EP1291022A1 (en) * | 1998-07-30 | 2003-03-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods of using lanreotide, a somatostatin analogue |
| AU771034B2 (en) | 1998-11-24 | 2004-03-11 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
| JP2000226400A (ja) * | 1998-12-04 | 2000-08-15 | Nippon Kayaku Co Ltd | アポトーシス制御能を有する蛋白質、その遺伝子及びそれらの用途 |
| CA2499211A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Modified peptides yy and conjugates thereof |
| AU5836700A (en) * | 1999-06-01 | 2000-12-18 | Patrick T. Prendergast | Peptides for therapeutic use |
| US7176279B2 (en) * | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| EP1593384A3 (en) * | 1999-06-29 | 2006-04-26 | Palatin Technologies, Inc. | Compositions for treatment of sexual dysfunction |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| WO2001087328A2 (en) * | 2000-05-12 | 2001-11-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| WO2002051232A2 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| US6660756B2 (en) * | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| WO2002092018A2 (en) * | 2001-05-16 | 2002-11-21 | Plotnikoff Nicholas P | Methods for inducing sustained immune response |
| EP1314357B1 (en) | 2001-11-23 | 2007-05-23 | Société des Produits Nestlé S.A. | Process for the preparation of milk powders and concentrated milk products |
| JP2003267992A (ja) * | 2002-03-18 | 2003-09-25 | Makoto Fujii | 抗酸化剤、老化防止剤および／または抗ガン剤 |
| US7034004B2 (en) * | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| CA2499580A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| AU2003284428B2 (en) * | 2002-11-27 | 2010-08-26 | Ils Inc. | Peptides and medicinal compositions containing the same |
| US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| US20050101535A1 (en) * | 2003-05-06 | 2005-05-12 | Rosenstein David H. | Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain |
| US20070248584A1 (en) * | 2003-06-10 | 2007-10-25 | The University Of Melbourne | Immunomodulating Compositions, Uses Therefore and Processes for Their Production |
| WO2005004899A2 (de) * | 2003-07-14 | 2005-01-20 | Mondobiotech Laboratories Anstalt | Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070053954A1 (en) * | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
| CA2563882A1 (en) * | 2004-04-23 | 2005-11-03 | Senju Pharmaceutical Co., Ltd. | Corneal neuritogenesis promoter containing pacap and its derivative |
| WO2006039326A2 (en) * | 2004-09-29 | 2006-04-13 | The Administrators Of The Tulane Educational Fund | Inhibitors of hepatitits c virus |
| EP1863847A2 (en) * | 2004-12-02 | 2007-12-12 | Domantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| ES2336826T3 (es) * | 2005-05-03 | 2010-04-16 | Novetide, Ltd. | Procedimientos para la produccion de un peptido que presenta una amida c-terminal. |
| CA2624153A1 (en) * | 2005-09-29 | 2007-04-12 | The Scripps Research Institute | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family |
| WO2007060692A2 (en) * | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| JP2009530234A (ja) * | 2006-03-17 | 2009-08-27 | ステム セル セラピューティクス コーポレイション | 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン |
| UA22357U (en) * | 2006-10-25 | 2007-04-25 | Inst Surgery Transplantation | Method for treatment of pancreatic pseudocyst and of parapancreatic liquid accumulation |
| WO2008086042A2 (en) * | 2007-01-10 | 2008-07-17 | Chisari Francis V | Preventing infection by a measles or respiratory syncytial virus |
-
2008
- 2008-09-09 AU AU2008297535A patent/AU2008297535A1/en not_active Abandoned
- 2008-09-09 EP EP08802576A patent/EP2187931A2/en not_active Withdrawn
- 2008-09-09 JP JP2010523404A patent/JP5395793B2/ja not_active Expired - Fee Related
- 2008-09-09 CA CA2698912A patent/CA2698912A1/en not_active Abandoned
- 2008-09-09 EP EP08801995A patent/EP2190453A2/en not_active Withdrawn
- 2008-09-09 US US12/677,113 patent/US20100204135A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007511 patent/WO2009039969A2/en not_active Ceased
- 2008-09-09 JP JP2010523365A patent/JP5385276B2/ja not_active Expired - Fee Related
- 2008-09-09 JP JP2010523347A patent/JP2011505335A/ja active Pending
- 2008-09-09 CA CA2698666A patent/CA2698666A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007885 patent/WO2009033771A2/en not_active Ceased
- 2008-09-09 CA CA2710406A patent/CA2710406A1/en not_active Abandoned
- 2008-09-09 AU AU2008297915A patent/AU2008297915A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007744 patent/WO2009040035A2/en not_active Ceased
- 2008-09-09 US US12/677,542 patent/US20100204132A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007650 patent/WO2009033723A2/en not_active Ceased
- 2008-09-09 KR KR1020107005627A patent/KR20100058556A/ko not_active Ceased
- 2008-09-09 JP JP2010523418A patent/JP2010539045A/ja active Pending
- 2008-09-09 RU RU2010113989/15A patent/RU2010113989A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007625 patent/WO2009043454A2/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/007867 patent/WO2009033760A2/en not_active Ceased
- 2008-09-09 US US12/677,553 patent/US20100216724A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007438 patent/WO2009039958A1/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/008100 patent/WO2009043518A2/en not_active Ceased
- 2008-09-09 RU RU2010114007/15A patent/RU2010114007A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007451 patent/WO2009033664A1/en not_active Ceased
- 2008-09-09 RU RU2010113969/15A patent/RU2010113969A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007439 patent/WO2009039959A1/en not_active Ceased
- 2008-09-09 AT AT08802215T patent/ATE553772T1/de active
- 2008-09-09 WO PCT/EP2008/007680 patent/WO2009033741A2/en not_active Ceased
- 2008-09-09 KR KR1020107005587A patent/KR20100058546A/ko not_active Withdrawn
- 2008-09-09 US US12/677,347 patent/US20100210535A1/en not_active Abandoned
- 2008-09-09 CA CA2699047A patent/CA2699047A1/en not_active Abandoned
- 2008-09-09 JP JP2010523434A patent/JP2010539061A/ja active Pending
- 2008-09-09 US US12/676,924 patent/US20100204138A1/en not_active Abandoned
- 2008-09-09 AU AU2008297927A patent/AU2008297927A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007574 patent/WO2009033712A2/en not_active Ceased
- 2008-09-09 US US12/677,810 patent/US20100184679A1/en not_active Abandoned
- 2008-09-09 RU RU2010114059/15A patent/RU2010114059A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007716 patent/WO2009040022A2/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/007522 patent/WO2009039978A2/en not_active Ceased
- 2008-09-09 KR KR1020107005643A patent/KR20100061485A/ko not_active Withdrawn
- 2008-09-09 EP EP08802215A patent/EP2197477B1/en not_active Not-in-force
- 2008-09-09 KR KR1020107005605A patent/KR20100071984A/ko not_active Ceased
- 2008-09-09 EP EP08802380A patent/EP2207560A2/en not_active Withdrawn
- 2008-09-09 AU AU2008306130A patent/AU2008306130A1/en not_active Abandoned
- 2008-09-09 EP EP08785858A patent/EP2192915A1/en not_active Withdrawn
- 2008-09-09 RU RU2010114034/15A patent/RU2010114034A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005668A patent/KR20100063717A/ko not_active Withdrawn
- 2008-09-09 EP EP08802082A patent/EP2187901B1/en not_active Not-in-force
- 2008-09-09 WO PCT/EP2008/007654 patent/WO2009033726A2/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/007432 patent/WO2009033657A2/en not_active Ceased
- 2008-09-09 CA CA2698833A patent/CA2698833A1/en not_active Abandoned
- 2008-09-09 AU AU2008303940A patent/AU2008303940A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114007A (ru) | Применение комбинации пептидов cart в качестве терапевтического средства | |
| RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
| RU2010114057A (ru) | Применение натрийуретического пептида с-типа индивидуально или в сочетании с нейропептидом af в качестве терапевтического средства | |
| RU2010114002A (ru) | Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
| RU2010113992A (ru) | Применение урокортина и кортиколиберина в качестве терапевтических средств | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113976A (ru) | Применение glp-1 в качестве терапевтического средства | |
| RU2010114044A (ru) | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
| RU2010114047A (ru) | Применение нейропептида af человека в качестве терапевтического средства | |
| RU2010113999A (ru) | Применение секретина и необязательно уродилатина в качестве терапевтических средств | |
| RU2010114017A (ru) | Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43 | |
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
| WO2009033668A3 (en) | Use of a peptide as a therapeutic agent | |
| RU2010114019A (ru) | Минигастрин в качестве терапевтического средства | |
| RU2010113984A (ru) | Применение врр-в в качестве терапевтического средства | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
| RU2010114060A (ru) | Применение пептида в качестве терапевтического средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |